The present study was designed to investigate the effect of a selective
GABA(B) receptor agonist baclofen on the
pain-like nociceptive behavior (scratching, biting and licking) induced by intrathecal (i.t.) injection of
N-methyl-D-aspartate (
NMDA) or (+)
TAN-67, the enantiomorphs of 2-methyl-4aalpha-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aalpha-octahydro-quinolino[2,3,3g]
isoquinoline (TAN-67), in the mouse.
NMDA (0.05-0.2 microg/mouse) given i.t. immediately caused nociception in a dose-dependent manner. The nociception was significantly antagonized by i.t. co-injection with dizocilipine (0.1-1.0 microg/mouse), a non-competitive
NMDA receptor antagonist. I.t. co-injection with
baclofen (37.5-150 ng/mouse) significantly reduced the
NMDA-induced nociceptive behavior in a dose-dependent fashion. The inhibition produced by
baclofen was completely reversed by a selective
GABA(B) receptor antagonist 2-hydroxysaclofen (0.15 and 0.3 microg/mouse). An i.t. injection of (+)
TAN-67 at doses of 3.75-15 microg/mouse elicited a long-lasting and a dose-related nociception. The nociceptive behavior induced by (+)
TAN-67 given i.t. was markedly suppressed by i.t. co-injection with
baclofen (3-30 ng/mouse), and the inhibitory effect of
baclofen was prevented by i.t. injection of
2-hydroxysaclofen (1 and 3 microg/ mouse). In addition, the (+)
TAN-67-induced nociception was also attenuated by i.t. co-injection with dizocilipine (0.1-1.0 microg/mouse). These results suggest that spinal
GABA(B) receptors may be implicated in the expression of nociception elicited by i.t. injection of either
NMDA or (+)
TAN-67 in the mouse.